Upsher-Smith inks generic development, distribution agreement with Pharmathen

MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Tuesday announced an exclusive agreement with Pharmathen to develop and distribute a generic product in a market category that had more than $500 million in sales for the 12 months ended July 2016, according to IMS Health data. 

 

Under the agreement, Pharmathen will develop, manufacture and supply the product, and Upsher-Smith will submit the product for Food and Drug Administration approval and handle marketing and distributing in the United States as an Upsher-Smith generic. 

 

“Upsher-Smith is pleased to collaborate with Pharmathen, one of the fastest growing generic companies in Europe,” Upsher-Smith president Rusty Field said. “Our commitment to quality and cost-effective products, coupled with the highest level of customer support, has helped make Upsher-Smith a trusted partner in the U.S. generics marketplace.”

 

Financial terms of the agreement have not been disclosed.